- Rubicon Point Partners Acquires Shockwave Medical Headquarters Campus in Santa Clara, California
May 14, 2026 · globenewswire.com
SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Rubicon Point Partners (“RPP”) announces the acquisition of the Shockwave Medical headquarters, a 201,078-square-foot, four-building R&D campus in Santa Clara, California, on behalf of Rubicon Point Fund II. The property is 100% NNN leased to Shockwave Medical, Inc., a medical device company and wholly owned subsidiary of Johnson & Johnson (S&P: AAA).
- RUBICON POINT PARTNERS ACQUIRES SHOCKWAVE MEDICAL HEADQUARTERS CAMPUS IN SANTA CLARA, CALIFORNIA
May 14, 2026
SAN FRANCISCO, MAY 14, 2026 (GLOBE NEWSWIRE) -- RUBICON POINT PARTNERS (“RPP”) ANNOUNCES THE ACQUISITION OF THE SHOCKWAVE MEDICAL HEADQUARTERS, A 201,078-SQUARE-FOOT, FOUR-BUILDING R&D CAMPUS IN SANTA CLARA, CALIFORNIA, ON BEHALF OF RUBICON POINT FUND II. THE PROPERTY IS 100% NNN LEASED TO SHOCKWAVE MEDICAL, INC., A MEDICAL DEVICE COMPANY AND WHOLLY OWNED SUBSIDIARY OF JOHNSON & JOHNSON (S&P: AAA).
- Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems
Mar 24, 2026
SAN CARLOS, Calif., March 24, 2026 /PRNewswire/ -- Sonder Capital, a healthcare venture capital firm investing in companies revolutionizing the standard of care, today announced the closing of its second fund, Futures II.Sonder Capital Logo
The fund includes participation from Mayo Clinic and Sutter Health, reflecting their collective interest in innovative technologies that have the potential to advance the future of patient care by enhancing access, improving quality and transforming the overall patient experience.
"Through our second fund we'll continue enabling the next wave of companies and healthcare technologies reshaping medicine," said Kate Garrett, Managing Partner at Sonder Capital. "And through our collaboration with Mayo Clinic and Sutter Health, we're strengthening our ability to support portfolio companies with insights from frontline care delivery—helping founders ensure innovation directly translates into better patient care."
Futures II is anchored by an investment thesis focused on AI-enabled medical robotics and minimally invasive therapies, fueling companies creating entirely new care pathways and business models. The fund will back companies innovating in these categories to create new standards of care in distributed settings—shifting what can be treated, where it can be treated, and who can deliver it.
"Medical robotics has already transformed what's possible in the operating room—and we're now entering the next chapter," said Fred Moll, MD, Founding Partner at Sonder Capital. "The addition of AI is unlocking new levels of performance and automation across care pathways, accelerating a revolution that will benefit patients, clinicians, and health systems alike, around the world."
About Sonder Capital
Sonder's team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Guidant Corporation (NYSE: GDT), Shockwave Medical (NASDAQ:SWAV), Procept Biorobotics (NASDAQ:PRCT), Auris Health, and Reflexion Medical, among others. Sonder's extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare companies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, MD.
Story Continues
For more information, visit: www.sondercapital.com
Media Contact:
Marisa Meehan
Director of Investor Relations
marisa@sondercapital.comCision
View original content to download multimedia:https://www.prnewswire.com/news-releases/sonder-capital-closes-its-second-fund-and-announces-participation-from-major-healthcare-systems-302722456.html
View Comments
- Galvanize Therapeutics Appoints Laura Francis to its Board of Directors
Nov 24, 2025
REDWOOD CITY, Calif., Nov. 24, 2025 /PRNewswire/ -- Galvanize ("Galvanize") Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, today announced the appointment of Laura Francis to its Board of Directors.
An experienced medical technology executive, Francis is Chief Executive Officer and a Board of Directors member of SI-BONE, Inc., a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She previously served as Chief Financial Officer and Chief Operating Officer. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with public and private life science companies, including Auxogyn, now part of Progyny, Promega Corporation, and Bruker Corporation, where she currently serves as a board member. Previously, she was an Engagement Manager with McKinsey & Company and Audit Manager with Coopers & Lybrand, now PricewaterhouseCoopers.
Francis also served as a board member of Shockwave Medical, Inc., where Galvanize Chairman and CEO Doug Godshall previously served as President and CEO. Ms. Francis earned a B.B.A. in Accounting and Finance from the University of Wisconsin and an M.B.A. from Stanford University.
"Laura's deep expertise in leading innovative, high-growth, medtech companies rooted in strong financial governance makes her an outstanding addition to our board," Godshall said. "Her involvement comes at an important time for Galvanize. We are scaling our commercial organization and advancing our technical and clinical portfolios as we endeavor to make our therapies more readily available for the millions of patients who are underserved by today's approaches. I feel fortunate to have this opportunity to work with Laura again."
About Galvanize Therapeutics Galvanize™ aims to become the global leader in delivering medical technology innovations that drive biologic processes to treat a range of diseases, including solid tumors, and chronic bronchitis symptoms. The company is based in Redwood City, CA, and is developing and commercializing its revolutionary Aliya® PEF energy platform in the United States. For more information, please visit www.galvanizetx.com.Cision
View original content:https://www.prnewswire.com/news-releases/galvanize-therapeutics-appoints-laura-francis-to-its-board-of-directors-302623726.html
View Comments
- Bruker Appoints Laura Francis to its Board of Directors
Feb 21, 2025
BILLERICA, Mass., February 21, 2025--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker’s Audit Committee as a financial expert after Bruker’s annual shareholder meeting at the end of May 2025.
Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with public and private life science companies, including Bruker Corporation, as well as Auxogyn, now part of Progyny (Nasdaq: PGNY), and Promega Corporation. Earlier in her career, she was an Engagement Manager with McKinsey & Company and Audit Manager with Coopers & Lybrand, now PricewaterhouseCoopers.
Ms. Francis previously also was a board member of Shockwave Medical, Inc. (Nasdaq: SWAV), a medical device company, where she served as audit committee chair and compensation committee member. Ms. Francis earned a B.B.A. in Accounting and Finance from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California.
"I am honored to join the Board of Directors at Bruker Corporation, a company I deeply respect and had the privilege of serving as CFO earlier in my career," said Ms. Francis. "I look forward to contributing to Bruker’s continued innovation and growth in the life sciences and diagnostics industries."
Frank H. Laukien, chairman, president and CEO of Bruker Corporation stated: "On behalf of our board and entire company, we warmly welcome Laura to our board of directors. Her experience as a public company medtech CEO, along with her CFO and COO experience in both the medtech and life science tools industries is going to be very valuable in guiding Bruker’s profitable growth and strategy execution. Laura is an impressive and accomplished leader, and she is a wonderful addition to our board."
About Bruker Corporation – Leader of the Post-Genomic Era
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Story Continues
Forward-Looking Statements
Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, those risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2023, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250221837705/en/
Contacts
Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
View Comments
- Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner
Oct 28, 2024
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner.Sonder Capital
Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered the use of person-generated health data and connected devices in decentralized research and large-scale health programs. Prior to Evidation, Kilpatrick held leadership roles in medical device and molecular diagnostic companies, including multiple roles at Guidant Corporation such as Research Fellow, Director of Research and Technology Development, and Director of New Ventures, prior to its acquisition by Boston Scientific. She is the co-Founder of MedtechWomen and the MedtechVision Conference, held annually in Silicon Valley and currently serves on the Board of Directors at Sleep Number (NASDAQ:SNBR), NextGen Jane, and Sutter Health, one of the largest and most innovative healthcare systems in the US providing care to millions throughout California.
Kilpatrick's background in medical devices coupled with her expertise in digital health technology will strengthen the Sonder team's ability to navigate and identify future investments in the medtech sector as it rapidly evolves to integrate multi-modal health data and AI.
"I'm excited to join the Sonder team and be a part of creating what's next in medtech," said Kilpatrick. "There is no doubt that the sector has driven better patient outcomes for decades. But I believe medtech is entering a new era where novel technologies will drive entirely new standards of care and transform both the clinician and patient experience in ways we are just beginning to imagine."
"We couldn't be more excited to welcome Deb to the Sonder team," said Kate Garrett, Managing Partner of Sonder Capital. "The future of the medtech industry will become a convergence of big data, AI and connected devices, creating unprecedented opportunities to improve healthcare. With a career deeply rooted in all of these areas, Deb brings unparalleled expertise to our team. Beyond that, Deb has been a champion of women leaders in the healthcare sector her entire career, something I and thousands of others have benefitted from. We are thrilled to be working side by side with her."
Story Continues
About Sonder Capital
Sonder's team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Shockwave Medical (NASDAQ:SWAV), Procept Biorobotics (NASDAQ:PRCT), Auris Health, and Reflexion Medical, among others. Sonder's extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D
Contacts Marisa Meehan, Sonder Capital
marisa@sondercapital.comCision
View original content to download multimedia:https://www.prnewswire.com/news-releases/deborah-kilpatrick-joins-sonder-capital-as-its-newest-venture-partner-302288301.html
SOURCE Sonder Capital
View Comments
- 7 Overlooked Stocks That Belong in Every Portfolio
Jun 3, 2024
The financial media does its best to keep you informed about what’s happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards. That creates an opportunity for investors who have the patience to look for must-own overlooked stocks.
Overlooked stocks are not necessarily underperforming the market. In some cases, these stocks simply are slow and steady at a time when investors want to find the newest and brightest shiny object.
However, not every shiny object is Nvidia (NASDAQ:NVDA). And the more light that starts shining on a high-profile stock, the more likely it is that the stock could move sharply lower on the slightest bit of bad news.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Another common misconception about overlooked stocks is that they come with a cheap price tag. This is also not necessarily true. In fact, sometimes a stock gets overlooked because it seems too expensive for retail investors.
In the end, must-buy overlooked stocks come down to value more than price. Because value always wins out over time. Here are seven stocks that investors are overlooking now but may shift back towards when market conditions change.
AbbVie (ABBV) Closeup of AbbVie (ABBV) building corporate office, an American biopharmaceutical company with its headquarters in Lake Bluff, Illinois, USA
Source: Valeriya Zankovych / Shutterstock.com
AbbVie (NYSE:ABBV) is up 13.4% in the last 12 months but is down 11% in the last three months. The biopharmaceutical giant is being overlooked for a couple of reasons. First, with a price-to-earnings (P/E) ratio of around 40x, it’s hardly a cheap stock. Second, investors want to see how the company’s revenue and earnings will hold up now that its flagship Humira drug faces biosimilar competition in the U.S. and Europe.
When looking at the P/E ratio it’s helpful to note that AbbVie has a forward P/E of around 13x earnings. That’s much more attractive.
Then there’s the Humira question. There’s no doubt that the company is seeing pressure from competitors. In its April earnings report, AbbVie reported a 39% decline in Humira revenue in the United States.
However, AbbVie also reported strong growth from two of its newer drugs: Skyrizi and Rinvoq. These drugs are integral to the company’s plans for replacing the lost Humira revenue. AbbVie also has a deep pipeline with 50 drugs in mid- and late-stage development.
Since the company’s earnings report, analysts have assigned a consensus price target of $182.90. That’s a 17% gain. Plus, AbbVie is a dividend king that not only has increased its dividend for 52 consecutive years, but the stock has an attractive yield of 3.98%.
Story continues
Johnson & Johnson (JNJ) jnj healthcare stocks
Source: Raihana Asral / Shutterstock.com
Johnson & Johnson (NYSE:JNJ) is another biopharmaceutical company on this list of must-own overlooked stocks. Unlike AbbVie, investors can’t say that JNJ stock is expensive. It has a current P/E of 9x and a forward P/E of 13x.
Nevertheless, valuation remains an issue as investors are trying to price JNJ stock without its consumer products division that it spun off as Kenvue (NYSE:KVUE) in 2023. The company is also working to resolve its long-running lawsuits stemming from its talc powder. In January, AbbVie announced it was moving forward on a $6.475 billion proposed settlement of tens of thousands of lawsuits. However, there may still be some work to do.
The past shouldn’t be overlooked. But the bullish case for JNJ stock is about the future. And its acquisition of Shockwave Medical (NASDAQ:SWAV) is a key part of that. The $13.1 billion acquisition will bring Shockwave’s first-to-market intravascular lithotripsy technology (ILT) under Johnson & Johnson’s MedTech division.
Once this acquisition becomes accretive to JNJ’s top and bottom lines, JNJ stock will look extremely attractive for more than just its dividend which has a 3.48% yield. And with 62 years of consecutive dividend increases, Johnson & Johnson is another dividend king on this list.
PepsiCo (PEP) Pepsi (PEP) Factory in Samara, Russia. Pepsi logo on a blue warehouse.
Source: FotograFFF / Shutterstock
PepsiCo (NASDAQ:PEP) is the third and final dividend king on this list of must-own overlooked stocks. The consumer staples giant has been largely able to pass along some of its higher producer costs. But growth is slowing, and there is concern that consumer spending is slowing as well. Just as Pepsi benefits from both beverage and snack food sales when consumers trade up, it can suffer when consumers trade down.
This pessimism is reflected in PEP stock, which is essentially flat in 2024 and down about 5% in the last 12 months. That’s not a massive dip to buy, but the stock is trading at around $170 which has served as a level of support and resistance in the last two years.
History shows that buying dips, no matter how small, in PEP stock is a solid strategy. One reason has to do with the company’s previously mentioned dividend which yields 2.96% as of this writing and has been growing for 53 consecutive years.
Sofi Technologies (SOFI) SoFi Technologies, Inc logo with stock market chart background. is an American online personal finance company and online bank.
Source: Poetra.RH / Shutterstock.com
Sofi Technologies (NASDAQ:SOFI) falls under the category of “yeah, but” stocks. Okay, I invented the category, but the premise is this. Sofi has largely delivered what it has said it would do. It was an online lender primarily known for providing student loans. Yeah, but it wasn’t a real bank. Then it got its bank charter. Yeah, but it wasn’t profitable. Now it’s delivered two straight quarters of positive adjusted EPS.
Still the stock can’t seem to get out of the snares of short sellers. A considerable 18% of the SOFI stock float is being shorted. And with only 38% of the shares owned by institutions, it’s been a tough hold.
SOFI stock is bouncing around $6.80. The good news is this has been a solid level of support. The bad news is that the company continues to revisit this level. The key will come from future growth, and in that regard being an internet-only bank lowers the company’s customer acquisition costs.
Pfizer (PFE) blue Pfizer logo on the windows of a corporate building PFR stock
Source: photobyphm / Shutterstock.com
Pfizer (NYSE:PFE) is down 24% in the last 12 months and nearly 50% since its peak of near $60 in November 2021. The rise and fall of PFE stock was entirely predictable. The company was first-to-market with a vaccine for Covid-19. And it enjoyed the benefits of that position in its revenue and earnings.
However, as demand for the company’s Covid-19 products wanes, so does the stock which is facing difficult comparisons. That said, Pfizer is being overlooked for many reasons, some of which have nothing to do with the intrinsic value of the stock.
That’s part of the buying thesis. The mRNA technology that was used in the Covid-19 vaccine is already being used to develop other vaccines. The company is also making strides in oncology as well as areas such as gene therapy and precision medicine. And Pfizer has the balance sheet to get these products to the finish line whether it goes alone or through acquisition.
Analysts have a consensus Hold rating on PFE stock, but the price target is 37% higher. That’s a discrepancy that makes it tempting to start a position. That’s particularly true because, while you wait, you’re getting a dividend with a 5.97% yield.
Enphase Energy (ENPH) Smartphone with logo of American company company Enphase Energy Inc. (ENPH) on screen in front of business website. Focus on left of phone display. Unmodified photo.
Source: T. Schneider / Shutterstock.com
Solar stocks have been hit and miss for investors. There are stocks like First Solar (NASDAQ:FSLR) that are ripping higher. But a company like Enphase Energy (NYSE:ENPH), which was a darling of the solar sector in 2021 and 2022 has been having a rough time.
The company serves a largely residential audience and has been faced with declining revenue which has caused earnings to turn negative. Simply put, Enphase desperately needs a rate cut that will stimulate home buying and consumer investment in solar technology.
That may have to wait until 2025, but here’s why you may want to put Enphase on a list of must-own overlooked stocks. Analysts have a consensus price target of $127.12. That’s 2% lower than the price as of this writing. But 22 out of 42 analysts give ENPH stock a Strong Buy or Buy rating. That suggests there may be a bigger dip coming for ENPH stock, but that would be a good time to take a position.
Norwegian Cruise Line (NCLH) Norwegian Cruise Line ship arriving at a port. NCLH stock.
Source: Ian_Stewart / Shutterstock
Cruise line stocks were a no-brainer long-term buy in 2020 and 2021. The industry was decimated by the global pandemic. But the smart money knew the industry would come back as it has. However, Norwegian Cruise Line (NYSE:NCLH) has been largely ignored. Investors have a high bar and little patience. All it took was a slight miss on the top line to spook investors and turn NCLH stock negative for the year.
But this could be the stock’s time to shine. Analysts are lining up behind Norwegian on expectations of earnings growth that could reach 30%, not just this year but for each of the next three years. That would help the cruise line retire a significant chunk of the $14 billion net debt load it’s still carrying.
To deliver on those projections, it seems like the company is counting on younger travelers. The company recently cited millennial and Gen-Z passengers as being its fastest growing demographic. That could be a double-edged sword if the economy worsens. However, over time these are the passengers that will have growing income to spend on experiences.
On the date of publication, Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.
More From InvestorPlace
The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future”
The post 7 Overlooked Stocks That Belong in Every Portfolio appeared first on InvestorPlace.
View comments
- Here’s Why Shockwave Medical (SWAV) Surged in Q1
May 30, 2024
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. Mid-cap stocks demonstrated strength carried over from the end of last year, delivering robust returns during the first quarter. Among the style indexes, the Russell Midcap Growth Index outperformed the Russell Midcap Value Index by a modest margin, with growth up 9.49% and value up 8.23%. All sectors in the Russell Midcap Growth Index delivered positive gains during the quarter. In addition, you can check the top 5 holdings of the fund to know its best picks in 2023.
Carillon Eagle Mid Cap Growth Fund highlighted stocks like Shockwave Medical, Inc. (NASDAQ:SWAV), in the first quarter 2024 investor letter. Shockwave Medical, Inc. (NASDAQ:SWAV) is a medical device company. The one-month return of Shockwave Medical, Inc. (NASDAQ:SWAV) was 1.46%, and its shares gained 18.88% of their value over the last 52 weeks. On May 29, 2024, Shockwave Medical, Inc. (NASDAQ:SWAV) stock closed at $334.83 per share with a market capitalization of $12.571 billion.
Carillon Eagle Mid Cap Growth Fund stated the following regarding Shockwave Medical, Inc. (NASDAQ:SWAV) in its first quarter 2024 investor letter:
"Shockwave Medical, Inc. (NASDAQ:SWAV) is a medical device company focused on developing products to treat calcified cardiovascular disease. The company beat consensus estimates, delivering solid revenue growth in the quarter driven largely by notably strong results in its intravascular lithotripsy (IVL) cardiovascular franchise. We remain positive on the company’s outlook given its growing international footprint and its plan to introduce new products, one which was recently approved ahead of schedule. Additionally, a large pharmaceutical company was just reported in the news as being in talks to potentially acquire the company."
A medical device company executive presenting the workings of intravascular lithotripsy technology.
Shockwave Medical, Inc. (NASDAQ:SWAV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Shockwave Medical, Inc. (NASDAQ:SWAV) at the end of the first quarter which was 40 in the previous quarter. Johnson and Johnson announced the acquisition of Shockwave Medical, Inc. (NASDAQ:SWAV) and expected to complete the deal in 2024.
In another article, we discussed Shockwave Medical, Inc. (NASDAQ:SWAV) and shared Baron Health Care Fund's views on the company. Shockwave Medical, Inc. (NASDAQ:SWAV) was one of the top contributors of Artisan Mid Cap Fund in the first quarter 2024. In addition, please check out our hedge fund investor letters Q1 2024 page for more investor letters from hedge funds and other leading investors.
Story continues
If you are looking for an AI stock that is as promising as Microsoft but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
View comments
- Sarepta Therapeutics Set to Join S&P MidCap 400
May 29, 2024
NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date Index Name Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care
For more information about S&P Dow Jones Indices, please visit www.spdji.com
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.
FOR MORE INFORMATION:
S&P Dow Jones Indices index_services@spglobal.com
Media Inquiries spdji.comms@spglobal.com Cision
View original content:https://www.prnewswire.com/news-releases/sarepta-therapeutics-set-to-join-sp-midcap-400-302158643.html
SOURCE S&P Dow Jones Indices
View comments
- Sarepta Therapeutics Set to Join S&P MidCap 400
May 29, 2024 · prnewswire.com
NEW YORK , May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.
